profit from every $100 of sales.
$0$100
TransMedics Group
$92.01+1.17% today
-24.7% in 1 year
1-year low $62.041-year high $150.42
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $16.79 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What TransMedics Group sold, what it kept, and what it did with the cash.
Sales went from $93.5 million in 2022 to $605 million in 2025, with $190 million of profit last year.
SalesProfit
TransMedics Group vs. similar companies
TransMedics Group grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| TransMedics Group | 16.8× · Fair price | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads TransMedics Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 93 | 242 | 442 | 605 | |
| 65 | 154 | 262 | 363 | |
| -31 | -29 | 37 | 109 | |
| -29 | -8 | 70 | 148 | |
| -36 | -25 | 35 | 190 | |
| -1.23 | -0.77 | 1.01 | 4.87 | |
| 69.8% | 63.8% | 59.4% | 59.9% | |
| -33.6% | -11.9% | 8.5% | 17.9% | |
| -38.8% | -10.4% | 8.0% | 31.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 277 | 706 | 804 | 1,068 |
| Cash | 201 | 395 | 337 | 488 |
| Total debt | 68 | 516 | 518 | 519 |
| Total liabilities | 90 | 569 | 575 | 595 |
| 187 | 137 | 229 | 473 | |
| 30 | 33 | 35 | 41 | |
| -10.1% | -1.9% | 5.3% | 9.7% | |
| -19.3% | -18.2% | 15.5% | 40.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -13 | 49 | 193 | |
| 12 | 179 | 130 | 59 | |
| -58 | -192 | -81 | 134 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 20 | 33 | 37 |
Valuation
- 16.8×
- 37.7×
- –
- 4.4×
- 5.3×
- 23.9×
- 21.7×
- 4.2%
- 6.0%
- 0.0%
Profitability
- 59.9%
- 17.9%
- 31.4%
- 21.6%
- 6.9%
- -6.5%
- 41.9%
- 12.0%
- 7.0%
- 12.1%
Growth
- +86.4%
- –
- +265.0%
- –
- +5.3%
Financial health
- 2.6×
- 1.66
- 57.1%
- 5.4×
- 6.74
- 6.19
- 0.44
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 958
Top 27%of 889
Top 27%of 601
Top 7%of 890
Top 27%of 987
What analysts expect
- Average price target
- $144.75
- Range
- $130.00 – $166.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.30 | 0.62 | −51.6% |
| Feb 24, 2026 | 0.57 | 0.41 | +39.0% |
| Oct 29, 2025 | 0.66 | 0.37 | +78.4% |
| Jul 30, 2025 | 0.92 | 0.48 | +91.7% |
| May 8, 2025 | 0.70 | 0.29 | +141.4% |
| Feb 27, 2025 | 0.19 | 0.22 | −13.6% |
| Oct 28, 2024 | 0.12 | 0.29 | −58.6% |
| Jul 31, 2024 | 0.35 | 0.21 | +66.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
44No pass
Philip Fisher
63Pass
Peter Lynch
86Pass
Joel Greenblatt
17No pass
Charlie Munger
40No pass
Terry Smith
44No pass
Questions about TransMedics Group
Is TransMedics Group a good stock to buy?
A strong, very profitable business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the TransMedics Group AI analysis
What does TransMedics Group do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. It is in Medical - Devices, based in Andover, MA, United States, with 898 employees.
Does TransMedics Group pay a dividend?
No. TransMedics Group does not pay a dividend at the moment.
Is TransMedics Group stock halal?
Yes. TransMedics Group passes our halal screen: its business is permitted and its debt is 16% of its market value, under the 30% limit. How we check
How has TransMedics Group stock done over the past year?
Down 24.7% over the past twelve months, to $92.01. It traded between $62.04 and $150.42 and is 38.8% below its high.
Who are TransMedics Group's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with TransMedics Group's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.